EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations

@inproceedings{Thunnissen2012EML4ALKTI,
  title={EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations},
  author={Erik B Thunnissen and Lukas Bubendorf and Manfred Dietel and G{\"o}ran P Elmberger and Keith M. Kerr and Fernando L{\'o}pez-R{\'i}os and Holger Moch and Wlodzimierz Olszewski and Patrick Pauwels and Fr{\'e}d{\'e}rique Penault-Llorca and Giulio Rossi},
  booktitle={Virchows Archiv},
  year={2012}
}

• Erik B Thunnissen, Lukas Bubendorf, +8 authors Giulio Rossi
• Published in Virchows Archiv 2012
• DOI:10.1007/s00428-012-1281-4

In non-small cell lung cancer, epidermal growth factor receptor gene mutations and anaplastic lymphoma kinase (ALK) gene rearrangements have a major impact upon the level of response to treatment with specific tyrosine kinase inhibitors. This review describes the molecular basis of ALK inhibition, summarizes current data on the effectiveness and safety of ALK inhibition therapy, describes the different testing methodologies with their advantages and disadvantages, provides a suggested testing… CONTINUE READING

Save to Library

Create Alert

Cite

View on Springer